Rallybio is a privately-held development-stage biotechnology company incorporated in January 2018. Our ambition is to create a world-leading biotechnology organization that transforms the lives of patients with devastating disease, built around people with an outstanding track record in pharmaceutical research and development. We will identify and accelerate the development of highly-promising drug candidates that have strong biological rationales and that can be addressed using the well-validated therapeutic modalities of small molecules, engineered proteins, and antibodies.
A part of the Technology Incubation Program at the University of Connecticut in Farmington, CT, Rallybio continues to expand our drug acquisition and development capabilities through the assembly of a team of individuals with an outstanding track record in pharmaceutical research and development, and a strong understanding of the financial components of the industry. This seasoned team enables us to search for and evaluate assets using a series of robust clinical and commercial filters that will allow us to identify and acquire a portfolio of high-quality small molecule and protein-based assets in the late discovery to early clinical stages of drug development.
Named by FierceBiotech as one of its “Fierce 15” Biotech Companies of 2018, the Company was recognized as being among “the most promising private biotech startups” of the year. Rallybio has earned the support of highly-respected investors in the bioscience sector and announced in April 2018 that it had secured $37.0 million in Series A funding with lead financing from 5AM Ventures, Canaan Partners, and New Leaf Venture Partners, and additional public-sector participation from Connecticut Innovations.